| Literature DB >> 18624432 |
Hubert W Vesper1, Nadia Slimani, Göran Hallmans, Anne Tjønneland, Antonio Agudo, Vassiliki Benetou, Sheila Bingham, Heiner Boeing, Marie-Christine Boutron-Ruault, H Bas Bueno-de-Mesquita, Dolores Chirlaque, Françoise Clavel-Chapelon, Francesca Crowe, Dagmar Drogan, Pietro Ferrari, Ingegerd Johansson, Rudolf Kaaks, Jakob Linseisen, Eiliv Lund, Jonas Manjer, Amalia Mattiello, Domenico Palli, Petra H M Peeters, Sabina Rinaldi, Guri Skeie, Antonia Trichopoulou, Paolo Vineis, Elisabet Wirfält, Kim Overvad, Ulf Strömberg.
Abstract
Acrylamide exposure was investigated in subgroups of the EPIC study population (510 subjects from 9 European countries, randomly selected and stratified by age, gender, and smoking status) using hemoglobin adducts of acrylamide (HbAA) and its primary metabolite glycidamide (HbGA). Blood samples were analyzed for HbAA and HbGA by HPLC/MS/MS. Statistical models for HbAA and HbGA were developed including body mass index (BMI), educational level, and physical activity. A large variability in acrylamide exposure and metabolism between individuals and country groups was observed with HbAA and HbGA values ranging between 15-623 and 8-377 pmol/g of Hb, respectively. Both adducts differed significantly by country, sex, and smoking status. HbGA values were significantly lower in high alcohol consumers than in moderate consumers. With increasing BMI, HbGA in nonsmokers and HbAA in smokers decreased significantly. In the assessment of potential health effects related to acrylamide exposure, country of origin, BMI, alcohol consumption, sex, and smoking status should be considered.Entities:
Mesh：
Substances：
Year: 2008 PMID： 18624432 DOI： 10.1021/jf703750t
Source DB: PubMed Journal: J Agric Food Chem ISSN： 0021-8561 Impact factor: 5.279